Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. (4th November 2015)

Record Type:: Journal Article
Title:: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. (4th November 2015)
Main Title:: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
Authors:: Harvey, Christopher
Elpek, Kutlu
Duong, Ellen
Simpson, Tyler
Shu, ChengYi J
Shallberg, Lindsey
Wallace, Matthew
Sathyanarayanan, Sriram
Mabry, Robert
Briskin, Michael
Michaelson, Jennifer
Gajewski, Thomas F
Abstract:
Is Part Of:: Journal for immunotherapy of cancer. Volume 3(2015)Supplement 2
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 3(2015)Supplement 2
Issue Display:: Volume 3, Issue 2 (2015)
Year:: 2015
Volume:: 3
Issue:: 2
Issue Sort Value:: 2015-0003-0002-0000
Page Start:
Page End:
Publication Date:: 2015-11-04
Subjects:: Ipilimumab -- Agonist Property -- Syngeneic Tumor -- Preferential Reduction -- Preclinical Tumor Model
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:: http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:: 10.1186/2051-1426-3-S2-O9 ↗
Languages:: English
ISSNs:: 2051-1426
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19195.xml